Comparison of the Effects of Dorzolamide/Timolol Fixed Combination versus Latanoprost on Intraocular Pressure and Ocular Perfusion Pressure in Patients with Normal-Tension Glaucoma: A Randomized, Crossover Clinical Trial

Na Young Lee, Hae-Young Lopilly Park, Chan Kee Park, Na Young Lee, Hae-Young Lopilly Park, Chan Kee Park

Abstract

Backgroud: To assess the noninferiority of a dorzolamide-timolol fixed combination (DTFC) versus latanoprost in terms of intraocular pressure (IOP) and to compare blood pressure (BP), ocular perfusion pressure (OPP) and diastolic ocular perfusion pressure (DOPP) between the latanoprost and DTFC groups in patients with normal-tension glaucoma (NTG).

Methods: Prospective, interventional, randomized, single-blinded, crossover design study. Patients with newly diagnosed NTG that had not been treated with a glaucoma medication in the most recent 2 months were recruited. In total, 44 patients with NTG were randomly allocated to one of two groups. Patients in group A were treated with DTFC, lubricant, and latanoprost for 4 weeks each, whereas patients in group B were treated with latanoprost, lubricant, and DTFC for 4 weeks each. Patients were examined on day 1 (without medication), week 4 (under medication), week 8 (without medication), and week 12 (under medication). At weeks 4 and 12, diurnal IOP, systolic and diastolic BP, and OPP were measured at 8:00 AM, 10:00 AM, 12:00 PM, 4:00 PM, and 8:00 PM.

Results: Baseline demographic characteristics showed no difference in terms of age, sex, central corneal thickness, spherical equivalent, or stage of glaucoma between the groups. The between-group difference was -0.19 ± 0.18 mmHg (mean ± SE, upper bound of one-sided 95% CI, 0.12). Diurnal IOP showed no difference between the groups with an average IOP reduction of 13.1% using latanoprost and 12.3% using DTFC. Diurnal systolic and diastolic BP were lower in the DTFC group than the latanoprost group; however, the difference between the groups was not statistically significant. Diurnal OPP and DOPP also showed no statistically significant difference between the groups.

Conclusions: IOP lowering efficacy of DTFC was noninferior to that of latanoprost in newly diagnosed NTG patients. There was no difference in BP, OPP, or DOPP between the latanoprost and DTFC groups. This prospective, randomized, single-blinded, crossover study demonstrated the noninferiority of DTFC versus latanoprost in terms of IOP in patients with NTG.

Trial registration: ClinicalTrials.gov NCT01175902.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Consort diagram.
Fig 1. Consort diagram.
NTG indicates normal tension glaucoma; IOP, intraocular pressure; OPP, ocular perfusion pressure; DTFC, dorzolamide/timolol fixed combination.
Fig 2. Mean intraocular pressure during the…
Fig 2. Mean intraocular pressure during the circadian curve for the three crossover phases: at baseline, after dorzolamide/timolol, and after latanoprost.
Vertical bars indicate the 95% confidence interval of the estimates.
Fig 3. Mean systolic and diastolic blood…
Fig 3. Mean systolic and diastolic blood pressure (BP) during the circadian curve for the three crossover phases: at baseline, after dorzolamide/timolol, and after latanoprost.
Vertical bars indicate the 95% confidence interval of the estimates.
Fig 4. Mean ocular perfusion pressure and…
Fig 4. Mean ocular perfusion pressure and diastolic ocular perfusion pressure during the circadian curve for the three crossover phases: at baseline, after dorzolamide/timolol, and after latanoprost.
Vertical bars indicate the 95% confidence interval of the estimates.

References

    1. Coleman AL. Glaucoma. Lancet. 1999;354:1803–1810.
    1. Kim CS, Seong GJ, Lee NH, Song KC; Namil Study Group, Korean Glaucoma Society. Prevalence of primary open-angle glaucoma in central South Korea the Namil study. Ophthalmology. 2011;118:1024–1030. 10.1016/j.ophtha.2010.10.016
    1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440.
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
    1. Igarashi R, Togano T, Sakaue Y, Yoshino T, Ueda J, Fukuchi T. Effect on Intraocular Pressure of Switching from Latanoprost and Travoprost Monotherapy to Timolol Fixed Combinations in Patients with Normal-Tension Glaucoma. J Ophthalmol. 2014; 2014: 720385 10.1155/2014/720385
    1. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116:1243–1249. 10.1016/j.ophtha.2009.01.036
    1. Crichton AC, Harasymowycz P, Hutnik CM, Behki R, Boucher S, Ibrahim F, et al. Effectiveness of dorzolamide-timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J Ocul Pharmacol Ther. 2010;26:503–511. 10.1089/jop.2010.0032
    1. Parmaksiz S, Yuksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73–80.
    1. Kim TW, Kim M, Lee EJ, Jeoung JW, Park KH. Intraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucoma. J Glaucoma. 2014;23:329–32. 10.1097/IJG.0b013e3182741f4d
    1. Galassi F, Giambene B, Varriale R. Systemic vascular dysregulation and retrobulbar hemodynamics in normal-tension glaucoma. Invest Ophthalmol Vis Sci. 2011;52:4467–4471. 10.1167/iovs.10-6710
    1. Sung KR, Lee S, Park SB, Choi J, Kim ST, Yun SC, et al. Twenty-four hour ocular perfusion pressure fluctuation and risk of normal-tension glaucoma progression. Graefes Arch Clin Exp Ophthalmol. 2008;246:389–396.
    1. Costagliola C, Parmeggiani F, Virgili G, Lamberti G, Incorvaia C, Perri P, et al. Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 2008;246:389–396.
    1. Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917–2923.
    1. Shoji T, Sato H, Mizukawa A, Hirota N, Enoki T, Kojima T, et al. Hypotensive effect of latanoprost/timolol versus travoprost/timolol fixed combinations in NTG patients: a randomized, multicenter, crossover clinical trial. Invest Ophthalmol Vis Sci. 2013;54:6242–6247. 10.1167/iovs.13-11942
    1. Chow SC, Chang M, Pong A. Statistical consideration of adaptive methods in clinical development. J Biopharm Stat. 2005;15:575–591.
    1. Janulevicienë I, Harris A, Kagemann L, Siesky B, McCranor L. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol. Scand. 2004:82:730–737.
    1. Pajic B. Conductors of the Swiss COSOPT Survey (CSCS). Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists’ offices. Curr Med Res Opin. 2003;19:95–101.
    1. Henderer JD, Wilson RP, Moster MR, Myers J, Schmidt C, Fontanarosa J, et al. Timolol/ dorzolamide combination therapy as initial treatment for intraocular pressure over 30mm Hg. J. Glaucoma. 2005;14:267–270.
    1. Ozyol E, Ozyol P. The efficacy of a latanoprost/timolol fixed combination versus latanoprost and timolol gel-forming solution unfixed combination on daytime intraocular pressure. J Glaucoma. 2014. September 26. [Epub ahead of print]
    1. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125:585–592.
    1. Fraunfelder ET. Ocular beta-blocker and systemic side effects. Arch Intern Med. 1986;146:1073–1074.
    1. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128:301–309.
    1. Gass A, Flammer J, Linder L, Romerio SC, Gasser P, Haefeli WE. Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 1997;235:634–638.
    1. Harris A, Jonescu-Cuypers CP, Kagemann L, Nowacki EA, Garzozi H, Cole C, et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am J Ophthalmol. 2001;132:490–495.
    1. Harris A, Arend O, Chung HS, Kagemann L, Cantor L, Martin B. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. Ophthalmology. 2000;107:430–434.
    1. Feke GT, Rhee DJ, Turalba AV, Pasquale LR. Effects of dorzolamide-timolol and brimonidine-timolol on retinal vascular autoregulation and ocular perfusion pressure in primary open angle glaucoma. J Ocul Pharmacol Ther. 2013;29:639–645. 10.1089/jop.2012.0271
    1. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19:87–112.
    1. Harris A, Migliardi R, Rechtman E, Cole CN, Yee AB, Garzozi HJ. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. Eur J Ophthalmol. 2003;13:24–31.
    1. Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006;50:153–157.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi